Promore Pharma AB (publ) (PROMO.ST) Research

Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to advancing peptide-based drug therapies. The company's development pipeline features PXL01, currently undergoing Phase IIa studies for its potential in preventing post-surgical adhesions and scars, mitigating dermal scarring, and aiding hand tendon repair. Another key asset, LL-37, is engaged in Phase IIb clinical trials to address venous leg ulcers, stimulate the healing of persistent wounds, and treat diabetic foot ulcers. Additionally, Promore Pharma has partnered with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. Founded in 2002, the company, formerly known as Lipopeptide AB until its rebranding in January 2017, maintains its headquarters in Solna, Sweden.

Market snapshot

Symbol
PROMO.ST
Price
$0.11
Day change
+13.17%
Market cap
$293.5M
P/E ratio
-0.25x
52-week range
0.045-1.995
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Asarina Pharma AB (publ) (ASAP.ST)
  • Cyxone AB (publ) (CYXO.ST)
  • Idogen AB (publ) (IDOGEN.ST)
  • ISR Immune System Regulation Holding AB (publ) (ISR.ST)
  • Kancera AB (publ) (KAN.ST)
  • Medhelp Care Aktiebolag (publ) (MEDHLP.ST)
  • Medivir AB (publ) (MVIR-B.ST)
  • Pharmiva AB (publ) (PHARM.ST)

Open Promore Pharma AB (publ) (PROMO.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.